Cargando…

Decitabine and Cisplatin are Synergistic to Exert Anti-Tumor Effect on Gastric Cancer via Inducing Sox2 DNA Demethylation

BACKGROUND: Cisplatin is a vital chemotherapy regimen for gastric cancer (GC), while partial response is observed (approximately 40%) because of drug resistance. Thus, it is urgent to improve drug sensitivity to improve the therapeutic effect of cisplatin on GC. PURPOSE: The study was performed to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zhipeng, Lin, Sihao, Wu, Xiaofang, Xu, Jiuhua, Li, Lulu, Ye, Weipeng, Li, Jiayi, Huang, Zhengjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837578/
https://www.ncbi.nlm.nih.gov/pubmed/33519210
http://dx.doi.org/10.2147/OTT.S276168
_version_ 1783642984084930560
author Zhu, Zhipeng
Lin, Sihao
Wu, Xiaofang
Xu, Jiuhua
Li, Lulu
Ye, Weipeng
Li, Jiayi
Huang, Zhengjie
author_facet Zhu, Zhipeng
Lin, Sihao
Wu, Xiaofang
Xu, Jiuhua
Li, Lulu
Ye, Weipeng
Li, Jiayi
Huang, Zhengjie
author_sort Zhu, Zhipeng
collection PubMed
description BACKGROUND: Cisplatin is a vital chemotherapy regimen for gastric cancer (GC), while partial response is observed (approximately 40%) because of drug resistance. Thus, it is urgent to improve drug sensitivity to improve the therapeutic effect of cisplatin on GC. PURPOSE: The study was performed to explore the synergistic effect of decitabine and cisplatin in GC. MATERIALS AND METHODS: Cancer and matched adjacent tissues from patients with GC were obtained and quantitative real-time PCR (qRT-PCR), Western blot and immunohistochemistry were performed to evaluate Sox2 expression level. Methylation-specific PCR (MSP) was performed to assess the effect of 5-aza-2ʹ-deoxycytidine (5-Aza-CdR) on Sox2 promoter. Cell proliferation assay, scratch-wound migration assay and Transwell invasion ability were performed to assess the effect of 5-Aza-CdR on proliferation, migration and invasion ability. Meantime, the effect of 5-Aza-CdR was also investigated in gastric cell lines BGC-823 and nude mouse xenograft tumor model. Finally, the anti-cancer effect of decitabine, cisplatin and their combination treatment were investigated in a BGC-823 and nude mouse xenograft tumor model, Sox2 methylation level, Sox2 expression of BGC-823 and xenograft tumors were analyzed by MSP, qRT-PCR and Western blot. RESULTS: Sox2 expression was significantly associated with different differentiated degrees, depth of invasion (0.0011), lymph node metastasis (0.0013), and TNM stage (0.0002). Next, methylation inhibitor 5-Aza-CdR restored Sox2 expression to promote proliferation, migration and invasion in vitro and in vivo. Finally, cisplatin and decitabine was found to be synergistic to inhibit proliferation of xenograft tumors. Likewise, cisplatin and decitabine were also synergistic to induce Sox2 DNA demethylation to promote Sox2 mRNA and protein expression in BGC-823 and xenograft tumors. CONCLUSION: Cisplatin and decitabine could be synergistic to induce Sox2 DNA demethylation to promote expression of the Sox2 gene, which exerted an anti-tumor effect on GC. It may suggest an insight for innovative therapeutics of GC.
format Online
Article
Text
id pubmed-7837578
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78375782021-01-28 Decitabine and Cisplatin are Synergistic to Exert Anti-Tumor Effect on Gastric Cancer via Inducing Sox2 DNA Demethylation Zhu, Zhipeng Lin, Sihao Wu, Xiaofang Xu, Jiuhua Li, Lulu Ye, Weipeng Li, Jiayi Huang, Zhengjie Onco Targets Ther Original Research BACKGROUND: Cisplatin is a vital chemotherapy regimen for gastric cancer (GC), while partial response is observed (approximately 40%) because of drug resistance. Thus, it is urgent to improve drug sensitivity to improve the therapeutic effect of cisplatin on GC. PURPOSE: The study was performed to explore the synergistic effect of decitabine and cisplatin in GC. MATERIALS AND METHODS: Cancer and matched adjacent tissues from patients with GC were obtained and quantitative real-time PCR (qRT-PCR), Western blot and immunohistochemistry were performed to evaluate Sox2 expression level. Methylation-specific PCR (MSP) was performed to assess the effect of 5-aza-2ʹ-deoxycytidine (5-Aza-CdR) on Sox2 promoter. Cell proliferation assay, scratch-wound migration assay and Transwell invasion ability were performed to assess the effect of 5-Aza-CdR on proliferation, migration and invasion ability. Meantime, the effect of 5-Aza-CdR was also investigated in gastric cell lines BGC-823 and nude mouse xenograft tumor model. Finally, the anti-cancer effect of decitabine, cisplatin and their combination treatment were investigated in a BGC-823 and nude mouse xenograft tumor model, Sox2 methylation level, Sox2 expression of BGC-823 and xenograft tumors were analyzed by MSP, qRT-PCR and Western blot. RESULTS: Sox2 expression was significantly associated with different differentiated degrees, depth of invasion (0.0011), lymph node metastasis (0.0013), and TNM stage (0.0002). Next, methylation inhibitor 5-Aza-CdR restored Sox2 expression to promote proliferation, migration and invasion in vitro and in vivo. Finally, cisplatin and decitabine was found to be synergistic to inhibit proliferation of xenograft tumors. Likewise, cisplatin and decitabine were also synergistic to induce Sox2 DNA demethylation to promote Sox2 mRNA and protein expression in BGC-823 and xenograft tumors. CONCLUSION: Cisplatin and decitabine could be synergistic to induce Sox2 DNA demethylation to promote expression of the Sox2 gene, which exerted an anti-tumor effect on GC. It may suggest an insight for innovative therapeutics of GC. Dove 2021-01-22 /pmc/articles/PMC7837578/ /pubmed/33519210 http://dx.doi.org/10.2147/OTT.S276168 Text en © 2021 Zhu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhu, Zhipeng
Lin, Sihao
Wu, Xiaofang
Xu, Jiuhua
Li, Lulu
Ye, Weipeng
Li, Jiayi
Huang, Zhengjie
Decitabine and Cisplatin are Synergistic to Exert Anti-Tumor Effect on Gastric Cancer via Inducing Sox2 DNA Demethylation
title Decitabine and Cisplatin are Synergistic to Exert Anti-Tumor Effect on Gastric Cancer via Inducing Sox2 DNA Demethylation
title_full Decitabine and Cisplatin are Synergistic to Exert Anti-Tumor Effect on Gastric Cancer via Inducing Sox2 DNA Demethylation
title_fullStr Decitabine and Cisplatin are Synergistic to Exert Anti-Tumor Effect on Gastric Cancer via Inducing Sox2 DNA Demethylation
title_full_unstemmed Decitabine and Cisplatin are Synergistic to Exert Anti-Tumor Effect on Gastric Cancer via Inducing Sox2 DNA Demethylation
title_short Decitabine and Cisplatin are Synergistic to Exert Anti-Tumor Effect on Gastric Cancer via Inducing Sox2 DNA Demethylation
title_sort decitabine and cisplatin are synergistic to exert anti-tumor effect on gastric cancer via inducing sox2 dna demethylation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837578/
https://www.ncbi.nlm.nih.gov/pubmed/33519210
http://dx.doi.org/10.2147/OTT.S276168
work_keys_str_mv AT zhuzhipeng decitabineandcisplatinaresynergistictoexertantitumoreffectongastriccancerviainducingsox2dnademethylation
AT linsihao decitabineandcisplatinaresynergistictoexertantitumoreffectongastriccancerviainducingsox2dnademethylation
AT wuxiaofang decitabineandcisplatinaresynergistictoexertantitumoreffectongastriccancerviainducingsox2dnademethylation
AT xujiuhua decitabineandcisplatinaresynergistictoexertantitumoreffectongastriccancerviainducingsox2dnademethylation
AT lilulu decitabineandcisplatinaresynergistictoexertantitumoreffectongastriccancerviainducingsox2dnademethylation
AT yeweipeng decitabineandcisplatinaresynergistictoexertantitumoreffectongastriccancerviainducingsox2dnademethylation
AT lijiayi decitabineandcisplatinaresynergistictoexertantitumoreffectongastriccancerviainducingsox2dnademethylation
AT huangzhengjie decitabineandcisplatinaresynergistictoexertantitumoreffectongastriccancerviainducingsox2dnademethylation